🧾 What This Document Is

This is a press release filed as an 8-K with the SEC. PepGen is sharing early, but important, clinical trial results for their lead drug candidate. Think of it as a public progress report for investors and the medical community. The headline is: their lowest dose appears safe and shows some promising, though mixed, signs of helping patients.

🏢 What The Company Does

👉 In simple terms, PepGen is a biotech startup trying to create groundbreaking medicines for severe brain and muscle diseases. They have a special technology platform (called EDO) designed to act like a precision delivery system, getting treatments directly to the faulty cells causing the illness.

🔬 The Science: How The Drug Works

This part is crucial. Their drug, PGN-EDODM1, is for Myotonic Dystrophy Type 1 (DM1), a serious genetic disease.

• The Problem: In DM1, a faulty gene creates "sticky" RNA traps inside cells. These traps snag important proteins (called MBNL1) that the cell needs to function properly.
• The Solution: PGN-EDODM1 is designed to be a smart blocker. It binds only to the faulty RNA, preventing it from trapping the MBNL1 proteins. This frees the proteins to do their normal job. 👉 Why it matters: Unlike some approaches that try to destroy the faulty RNA entirely, PepGen's method aims to leave the good parts of the RNA intact while only blocking the problematic part.

📊 The Clinical Trial Results (The Core News)

The company reported data from the lowest dose (5 mg/kg) group in their Phase 2 FREEDOM2 study. Here’s what they found:

Safety & Tolerability (👍 Good News):

• The drug was "generally well-tolerated." All side effects were mild or moderate.
• Crucially: No serious adverse events were reported. No patients quit the study due to side effects, and there were no signs of kidney problems or cumulative toxicity with repeated doses.

Efficacy Signals (🤔 Mixed & Nuanced): This is where the data gets complex. The main measure was "splicing correction" – essentially, how well the freed MBNL1 proteins start fixing the cell's RNA processing.

• The Headline Number: The 6 treated patients showed an average splicing correction of 7.3%, compared to 6.8% in the 2 placebo patients.
• The Important Detail: One treated patient was a dramatic "outlier" whose results worsened significantly (-70.8%). This dragged down the group's average.
• The Telling Number: If you remove that one outlier patient, the mean splicing correction for the other 5 patients jumps to 22.9%. This suggests the drug may be having a more substantial effect in most patients.
• Functional Trend: In a video-based hand movement test (vHOT), the treated group showed a promising positive trend compared to the placebo group, though benefits weren't permanent.

💰 Financial & Operational Guidance

Beyond the science, the company provided key forward-looking info:

• Cash Runway: They expect their current cash to fund operations into the second half of 2027. This tells investors how long they can run the company without needing more money.
• Next Milestone: They are on track to report data from a higher dose cohort (10 mg/kg) in the second half of 2026. This is the next major event investors will be watching.
• Enrollment: The higher-dose cohort is already more than halfway enrolled.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

• Favorable Safety Profile: The clean safety data at this dose is a significant positive, especially with no serious issues.
• Proof of Mechanism: The splicing data, particularly the 22.9% correction, provides evidence the drug is doing what it's designed to do at the cellular level.
• Regulatory Designations: The drug has Orphan Drug and Fast Track status from the FDA and Orphan status from the EMA, which can be helpful for development and future exclusivity.

⚠️ Risks & Caveats:

• Preliminary Data: This is from only 8 patients at the lowest dose. It's early and small-scale.
• Mixed Efficacy: The overall 7.3% splicing correction is modest and close to placebo. The standout results depend heavily on excluding one outlier.
• Functional Impact Not Yet Clear: No meaningful changes were seen in walking or grip strength at this dose. It's unclear if cellular improvements will translate to patients feeling better.
• Regulatory Hurdle: The filing notes the FDA has placed a "partial clinical hold" on the study. While the trial is ongoing, this indicates the agency has some concerns that need to be addressed.
• Future Unknown: There is no guarantee the drug will show better results at higher doses or ultimately win approval.

🔮 What's Next

The company's immediate focus is clear: continue dosing patients in the 10 mg/kg cohort and report that data in H2 2026. This higher dose will be critical in determining if the positive trends seen at 5 mg/kg strengthen into robust, clinically meaningful benefits.

🧠 The Analogy

Imagine the disease DM1 has glued the ignition key (MBNL1 protein) inside the car's steering column (the cell's nucleus). PGN-EDODM1 is like a slim, targeted pick designed to gently unstick just that one key, without breaking the column. The early results show the pick is working in most cars (freeing the key, improving splicing), but we won't know if the engine actually starts and runs smoothly (functional improvement) until we try a few more times and with a slightly different technique (higher doses).

📇 Key Contacts & People

• Investor Contact: Laurence Watts, New Street Investor Relations, [email protected]
• Media Contact: Julia Deutsch, Lyra Strategic Advisory, [email protected]
• Company Leadership Mentioned:
  • James McArthur, PhD, President and Chief Executive Officer
  • Paul Streck, MD, MBA, Head of R&D (EVP Research and Development)

🧩 Final Takeaway

PepGen's lowest dose of PGN-EDODM1 is safe and shows intriguing biological activity in most patients, supporting the need to test higher doses. The real test of whether this approach can transform DM1 treatment will come with the 10 mg/kg data expected in late 2026. Investors have a cash runway to see that through.